SCHEMBL14224045

SCHEMBL14224045

Cc1cc(CO)ncc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.54
DHFR P00374 1/20 0.40
MAP4K1 Q92918 2/20 0.36
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 1/20 0.36
NOS3 P29474 3/20 0.35
NOS1 P29475 3/20 0.35
NOS2 P35228 3/20 0.35
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
CYP1A2 P05177 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP7 P55210 1/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PIK3CA P42336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31230433 0.84 UHRF1 (0.50) UHRF1DHFRMAP4K1CYP3A4TSHR
SCHEMBL21666114 0.84 UHRF1 (0.50) UHRF1DHFRMAP4K1CYP3A4TSHR
SCHEMBL19171832 0.83 UHRF1 (0.43) UHRF1DHFRMAP4K1CYP3A4TSHR
SCHEMBL15417759 0.80 NOS3 (0.44) DHFRMAP4K1NOS3NOS1NOS2
SCHEMBL12452143 0.80 UHRF1 (0.38) UHRF1DHFRALDH1A1PIK3CAPI4KA
SCHEMBL30041599 0.80 UHRF1 (0.38) UHRF1DHFRALDH1A1PIK3CAPI4KA
SCHEMBL16804955 0.79 DHFR (0.38) UHRF1DHFRMAP4K1CYP3A4ALDH1A1
SCHEMBL6504147 0.77 UHRF1 (0.47) UHRF1CYP3A4TSHRMAPK1NOS3
SCHEMBL8683739 0.77 ALDH1A1 (0.36) DHFRMAP4K1CYP3A4MAPK1ALDH1A1
SCHEMBL18956959 0.76 UHRF1 (0.50) UHRF1CYP3A4TSHRMAPK1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911756-A2 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto Arena Pharmaceuticals, Inc. (US) 2008-04-16 EP disclosed